Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI · SINGLE PROTEIN · Staphylococcus aureus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI shows clinical signal disease relevance led by infection. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q6GI75. Start with infection, then reuse UniProt Q6GI75 as the stable protein anchor across project notes and exports.
Start with infection, then reuse UniProt Q6GI75 as the stable protein anchor across project notes and exports.
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI shows clinical signal disease relevance led by infection. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with infection because it currently carries clinical signal support. Linked drugs include AFABICIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI
Review this target as Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI, mapped to UniProt Q6GI75. Sequence length is 256 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI as ChEMBL target CHEMBL3994, mapped to UniProt Q6GI75. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI is the right protein anchor across sources, using UniProt Q6GI75 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why infection is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI |
| Target Type | SINGLE PROTEIN |
| Organism | Staphylococcus aureus |
| UniProt | Q6GI75 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI |
| UniProt Accession | Q6GI75 |
| Component Type | Protein |
| Sequence Length | 256 aa |
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI
Review this target as Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI, mapped to UniProt Q6GI75. Sequence length is 256 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI shows clinical signal disease relevance led by infection. 1 more disease program remain visible in the same review block.
Start review with infection because it currently carries clinical signal support. Linked drugs include AFABICIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3360252 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL5742155 | 10.05 | Ki | 0.09 | Preclinical |
| CHEMBL149299 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL148755 | 9.42 | Ki | 0.38 | Preclinical |
| CHEMBL149009 | 8.96 | Ki | 1.1 | Preclinical |
| CHEMBL488937 | 8.89 | Ki | 1.3 | Clinical |
| CHEMBL5966032 | 8.7 | Ki | 2.0 | Preclinical |
| CHEMBL6004349 | 8.57 | Ki | 2.7 | Preclinical |
| CHEMBL849 | 8.3 | Ki | 5.0 | Approved |
| CHEMBL2178304 | 8.1 | IC50 | 8.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 27 | 295 | 6.2 |
| assay format | 9 | 99 | 5.9 |